Authors

Peter R. Galle, MD, PhD, Mainz University Medical Center

Latest:

Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape

Discussion around topics pertaining to the use of systemic therapy in advanced liver cancer. Topics will include the latest research in the field and the impact of recent clinical trials on making decisions around treatment selection.

Peter Schmid, MD

Latest:

Dr. Schmid on Activity With Neoadjuvant Pembrolizumab in TNBC

Peter Schmid, MD, PhD, discusses the benefit of pembrolizumab when added to neoadjuvant chemotherapy in patients with triple-negative breast cancer.

Peter Schmid, MD, PhD

Latest:

Dr Rimm on Conceptual Considerations Surrounding ADC Mechanisms in Breast Cancer

David Rimm, MD, PhD, discusses key conceptual considerations and discrepancies regarding the mechanisms of action of ADCs in breast cancer treatment.

Peter Soyer, MD

Latest:

Dr. Soyer Discusses the Role of Technology in Melanoma

Peter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses the role of technology in melanoma.

Peter Voorhees, MD

Peter Voorhees, MD, is a member of the Hematology Department at Atrium Health Levine Cancer Institute and a professor of Cancer Medicine at the Wake Forest University School of Medicine in Charlotte, North Carolina.Peter Voorhees, MD

Latest:

Emerging Bispecifics and Trispecifics and Addressing Unmet Needs in R/R MM

Panelists discuss how trispecific antibodies targeting multiple antigens show promise for preventing antigen escape, while identifying ultrahigh-risk patients, frail patients, optimal treatment duration, and therapy access as key unmet needs.

Peter Voorhees, MD, UNC School of Medicine at Chapel Hill

Peter Yu, MD

Latest:

Dr. Yu Discusses Observation Versus Treatment in Men with Prostate Cancer

Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men's treatment decisions after seeing a raise in their PSA levels.

Petros Grivas, MD

Latest:

Dr Grivas on Addressing Unmet Needs in Urothelial Cancer

Petros Grivas, MD, PhD, discusses several unmet needs within urothelial cancer, as well as how to potentially ameliorate them.

Petros Grivas MD, PhD

Professor, Clinical Research Division, Fred Hutch, Clinical Director, Genitourinary Cancers Program, Fred Hutch

Latest:

Challenges in Standardizing ctDNA-guided MRD Testing in MIBC

Explore the challenges and advancements in ctDNA-based testing for cancer care, focusing on personalized approaches and sensitivity in diverse tumor types.

Phat Le, MD

Latest:

Dr. Le on Research Needed to Address Unmet Needs in mCRC

Phat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.

Phil Febbo, MD

Latest:

Dr. Febbo on the Impact of Oncotype DX Genetic Prostate Score

Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

Philip A. Philip, MD, Karmanos Cancer Center

Philip A. Philip, MD, PhD, FRCP

Latest:

Dr. Philip on Adverse Events With Lutathera in NETs

Philip A. Philip, MD, PhD, FRCP, professor of medicine, Wayne State University School of Medicine, clinical professor of oncology at Barbara Ann Karmanos Cancer Institute, discusses adverse events (AEs) associated with Lutathera (lutetium Lu 177 dotatate) in neuroendocrine tumors (NETs).

Philip A. Philip, MD, PhD, FRCP, Karmanos

Philip A. Philip, MD, PhD, FRCP, Wayne State University

Philip Agop Philip, MD, PhD, FRCP, Barbara Ann Karmanos Cancer Institute

Philip B. Paty, MD

Latest:

Dr. Paty on High-Risk Period for Rectal Tumor Regrowth

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.

Philip Bierman, MD

Latest:

Dr. Bierman on Unmet Needs for Patients With CNS Involvement in Aggressive NHL

Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses unmet needs for patients with central nervous system (CNS) involvement in aggressive subtypes of non–Hodgkin lymphoma (NHL).

Philip C. Mack, PhD, UC Davis Cancer center

Philip D. Bonomi, MD

Latest:

Dr. Bonomi Discusses PD-L1 as a Biomarker in NSCLC

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non-small cell lung cancer.